BRIEF-Reviva Announces Preliminary Topline Data For The Long-Term Open Label Extension Portion Of The Phase 3 Recover Study Evaluating Brilaroxazine In Schizophrenia

Reuters12-16

Dec 16 (Reuters) - Reviva Pharmaceuticals Holdings, Inc.

* REVIVA ANNOUNCES POSITIVE PRELIMINARY TOPLINE DATA FOR THE LONG-TERM OPEN LABEL EXTENSION PORTION OF THE PHASE 3 RECOVER STUDY EVALUATING BRILAROXAZINE IN SCHIZOPHRENIA

* FULL DATA SET FROM OPEN-LABEL EXTENSION (OLE) OF RECOVER EXPECTED IN Q1 2025

* ALL THREE DOSES OF BRILAROXAZINE (15 MG, 30 MG AND 50 MG) TESTED EFFICACIOUS & GENERALLY WELL-TOLERATED

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491696184?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-16 21:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491696184","market":"us","top_or_hot":-1,"title":"BRIEF-Reviva Announces Preliminary Topline Data For The Long-Term Open Label Extension Portion Of The Phase 3 Recover Study Evaluating Brilaroxazine In Schizophrenia","media":"Reuters","content":"<html><body><p>Dec 16 (Reuters) - <a href=\"https://laohu8.com/S/RVPH\">Reviva Pharmaceuticals Holdings, Inc.</a></p><p> :</p><p>   * REVIVA ANNOUNCES POSITIVE PRELIMINARY TOPLINE DATA FOR THE LONG-TERM OPEN LABEL EXTENSION PORTION OF THE PHASE 3 RECOVER STUDY EVALUATING BRILAROXAZINE IN SCHIZOPHRENIA</p><p>   * FULL DATA SET FROM OPEN-LABEL EXTENSION (OLE) OF RECOVER EXPECTED IN Q1 2025</p><p>   * ALL THREE DOSES OF BRILAROXAZINE (15 MG, 30 MG AND 50 MG) TESTED EFFICACIOUS &amp; GENERALLY WELL-TOLERATED</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Reviva Announces Preliminary Topline Data For The Long-Term Open Label Extension Portion Of The Phase 3 Recover Study Evaluating Brilaroxazine In Schizophrenia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Reviva Announces Preliminary Topline Data For The Long-Term Open Label Extension Portion Of The Phase 3 Recover Study Evaluating Brilaroxazine In Schizophrenia\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-16 21:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dec 16 (Reuters) - Reviva Pharmaceuticals Holdings, Inc. :   * REVIVA ANNOUNCES POSITIVE PRELIMINARY TOPLINE DATA FOR THE LONG-TERM OPEN LABEL EXTENSION PORTION OF THE PHASE 3 RECOVER STUDY EVALUATING...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVPH","symbol_name":"Reviva Pharmaceuticals Holdings, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2491696184","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491696184","pubTimestamp":1734356276,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Dec 16  - Reviva Pharmaceuticals Holdings, Inc. :   * REVIVA ANNOUNCES POSITIVE PRELIMINARY TOPLINE DATA FOR THE LONG-TERM OPEN LABEL EXTENSION PORTION OF THE PHASE 3 RECOVER STUDY EVALUATING BRILAROXAZINE IN SCHIZOPHRENIA   * FULL DATA SET FROM OPEN-LABEL EXTENSION  OF RECOVER EXPECTED IN Q1 2025   * ALL THREE DOSES OF BRILAROXAZINE  TESTED EFFICACIOUS & GENERALLY WELL-TOLERATEDSource text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RVPH":"Reviva Pharmaceuticals Holdings, Inc.","BK4007":"制药"},"translate_title":"简介-Reviva宣布评估Brilaroxazine治疗精神分裂症的3期Recover研究长期开放标签扩展部分的初步顶线数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVPH":0.9},"content_text":"Dec 16 (Reuters) - Reviva Pharmaceuticals Holdings, Inc. :   * REVIVA ANNOUNCES POSITIVE PRELIMINARY TOPLINE DATA FOR THE LONG-TERM OPEN LABEL EXTENSION PORTION OF THE PHASE 3 RECOVER STUDY EVALUATING BRILAROXAZINE IN SCHIZOPHRENIA   * FULL DATA SET FROM OPEN-LABEL EXTENSION (OLE) OF RECOVER EXPECTED IN Q1 2025   * ALL THREE DOSES OF BRILAROXAZINE (15 MG, 30 MG AND 50 MG) TESTED EFFICACIOUS & GENERALLY WELL-TOLERATEDSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491696184"}